Trials / Completed
CompletedNCT00762229
Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)
Prospective Evaluation of LDL Levels in Patients Converted From Zetia (Ezetimibe)10 mg to 5 mg
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Bronx VA Medical Center · Federal
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the effect on LDL cholesterol levels of converting patients who are receiving the cholesterol absorption inhibitor Zetia at a dose of 10 milligrams to 5 milligrams, when prescribed as a split 10 milligram tablet.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ezetimibe 10 mg | Ezetimibe 10 mg daily for 4 weeks |
| DRUG | Ezetimibe 5 mg | Ezetimibe 5 mg daily for 4 weeks, "formulated" as a 10 mg tablet split in half |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2008-09-30
- Last updated
- 2013-06-14
- Results posted
- 2013-06-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00762229. Inclusion in this directory is not an endorsement.